Literature DB >> 30017537

HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.

Luis Javier Galindo1, Tamara Hernández-Beeftink1, Ana Salas1, Yaiza Jung1, Ricardo Reyes1, Francisco Montes de Oca2, Mariano Hernández3, Teresa A Almeida4.   

Abstract

OBJECTIVE: Around 70% of uterine leiomyomas show MED12 mutations while overexpression of HMGA2 mRNA is also highly frequent in fibroids. However, previous studies suggested that alterations in both genes are mutually exclusive. In the present study, we searched for mutation in MED12 and analyzed the expression of HMGA2 in 20 uterine leiomyomas and their matched myometrium.
METHODS: Normal and tumor tissue obtained from premenopausal women who underwent hysterectomy were collected after surgery and DNA, RNA and proteins were isolated and analyzed for MED12 mutations using Sanger sequencing, HMGA2 mRNA expression by quantitative PCR and HMGA2 protein detection by western blot and immunohistochemistry.
RESULTS: 75% of the tumors displayed MED12 mutation while 65% of them showed overexpression of HMGA2 mRNA in leiomyomata compared to myometrial tissues (p = 0,0008). Interestingly, 50% of the tumors showed mutations in MED12 and overexpression of HMGA2 mRNA simultaneously, suggesting that alterations in both genes are relatively frequent in uterine leiomyomas.
CONCLUSIONS: Contrary to the present findings, former studies showed that mutations in MED12 and overexpression of HMGA2 are mutually exclusive. Here, we observed that overexpression of HMGA2 mRNA in tumors measured by quantitative PCR and compared to myometrium is a common phenomenon in fibroids and is frequently associated with MED12 mutations. In addition, the common clonal origin of tumors overexpressing HMGA2 mRNA and its expression in few myometrial tissue points to HMGA2 up-regulation as an early event in leiomyoma tumorigenesis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gene expression; HMGA2; Leiomyoma; MED12; Mutation; Sequencing

Mesh:

Substances:

Year:  2018        PMID: 30017537     DOI: 10.1016/j.ygyno.2018.07.007

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  Clinico-pathological features of gynecological myopericytoma: a challenging diagnosis in an exceptional location.

Authors:  Fulvio Borella; Fabiola Lucchino; Luca Bertero; Marisa Ribotta; Isabella Castellano; Andrea Carosso; Stefano Cosma; Dionyssios Katsaros; Chiara Benedetto
Journal:  Virchows Arch       Date:  2019-08-13       Impact factor: 4.064

2.  Uterine cellular leiomyomas are characterized by common HMGA2 aberrations, followed by chromosome 1p deletion and MED12 mutation: morphological, molecular, and immunohistochemical study of 52 cases.

Authors:  Pavel Dundr; Mária Gregová; Jan Hojný; Eva Krkavcová; Romana Michálková; Kristýna Němejcová; Michaela Bártů; Nikola Hájková; Jan Laco; Michal Mára; Adéla Richtárová; Tomáš Zima; Ivana Stružinská
Journal:  Virchows Arch       Date:  2021-10-09       Impact factor: 4.064

3.  Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis.

Authors:  Lukas Krasny; Chris P Wilding; Emma Perkins; Amani Arthur; Nafia Guljar; Andrew D Jenks; Cyril Fisher; Ian Judson; Khin Thway; Robin L Jones; Paul H Huang
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

4.  Leiomyoma with KAT6B-KANSL1 fusion: case report of a rapidly enlarging uterine mass in a postmenopausal woman.

Authors:  Alessandra J Ainsworth; Nooshin K Dashti; Taofic Mounajjed; Karen J Fritchie; Jaime Davila; Rohini Mopuri; Rory A Jackson; Kevin C Halling; Jamie N Bakkum-Gamez; J Kenneth Schoolmeester
Journal:  Diagn Pathol       Date:  2019-04-25       Impact factor: 2.644

Review 5.  High Mobility Group AT-Hook 2 (HMGA2) Oncogenicity in Mesenchymal and Epithelial Neoplasia.

Authors:  Uchenna Unachukwu; Kiran Chada; Jeanine D'Armiento
Journal:  Int J Mol Sci       Date:  2020-04-29       Impact factor: 5.923

Review 6.  Pathogenomics of Uterine Fibroids Development.

Authors:  Vladislav S Baranov; Natalia S Osinovskaya; Maria I Yarmolinskaya
Journal:  Int J Mol Sci       Date:  2019-12-06       Impact factor: 5.923

Review 7.  Dietary Natural Compounds and Vitamins as Potential Cofactors in Uterine Fibroids Growth and Development.

Authors:  Iwona Szydłowska; Jolanta Nawrocka-Rutkowska; Agnieszka Brodowska; Aleksandra Marciniak; Andrzej Starczewski; Małgorzata Szczuko
Journal:  Nutrients       Date:  2022-02-09       Impact factor: 5.717

8.  Frequency of MED12 Mutation in Relation to Tumor and Patient's Clinical Characteristics: a Meta-analysis.

Authors:  Chao He; William Nelson; Hui Li; Ya-Dong Xu; Xue-Jiao Dai; Ying-Xiong Wang; Yu-Bin Ding; Yan-Ping Li; Tian Li
Journal:  Reprod Sci       Date:  2021-02-10       Impact factor: 3.060

Review 9.  Vitamins and Uterine Fibroids: Current Data on Pathophysiology and Possible Clinical Relevance.

Authors:  Michał Ciebiera; Mohamed Ali; Magdalena Zgliczyńska; Maciej Skrzypczak; Ayman Al-Hendy
Journal:  Int J Mol Sci       Date:  2020-08-01       Impact factor: 5.923

10.  Cytogenomic Profile of Uterine Leiomyoma: In Vivo vs. In Vitro Comparison.

Authors:  Alla S Koltsova; Olga A Efimova; Olga V Malysheva; Natalia S Osinovskaya; Thomas Liehr; Ahmed Al-Rikabi; Natalia Yu Shved; Iskender Yu Sultanov; Olga G Chiryaeva; Maria I Yarmolinskaya; Nikolai I Polenov; Vladislava V Kunitsa; Maka I Kakhiani; Tatyana G Tral; Gulrukhsor Kh Tolibova; Olesya N Bespalova; Igor Yu Kogan; Andrey S Glotov; Vladislav S Baranov; Anna A Pendina
Journal:  Biomedicines       Date:  2021-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.